All In Biotech

Drug Trial Radar · NCT00976378

NOX-A12 First-in-human (FIH) Study

NOX-A12 to Mobilize Stem Cells in Healthy Volunteers - A Single-center, Single Dose, Open Label, Dose Escalation Study of Intravenous NOX-A12 in up to 48 Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jun 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 2009

Primary completion

May 2010

Study completion May 2010

Sponsor

Lead sponsor
TME Pharma AGIndustry
Sponsor type
Industry
Collaborators
German Federal Ministry of Education and Research
First posted
Sep 14, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is the first time NOX-A12 will be administered to man. The principal aim of this study is to obtain safety and tolerability data when NOX-A12 is administered by single intravenous (IV) doses to healthy male and female subjects. This information, together with the pharmacokinetic and pharmacodynamic data, will help establish the doses and dosage regimen of administration suitable for subsequent studies in the patient population.

Conditions

  • Autologous Stem Cell Transplantation

Interventions

  • NOX-A12Drug

    single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg

  • NOX-A12Drug

    single IV dose, at efficacious dose level

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of NOX-A12 by means of adverse events, vital signs, laboratory parameters, 12-lead ECG and immunogenicity assessmentTime frame: 1 month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Scope Life Sciences GmbH

    Hamburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.